Differentiate your Omega 3 products with Croda
Croda
Breaking News on Supplements & Nutrition - EuropeUS edition
Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.
Spotlight
  Flavonols may slash risk of vascular disease for womenIncreased intake of flavonols from tea and other sources may boost heart health for older women, with... |
 Yakult ordered to pull Olympics-themed advert in UK over health claims breachThe UK Advertising Standards Authority (ASA) has slapped a ban on the broadcast of a Yakult TV... |
  All the latest news and tweets live from the showVitafoods Europe 2013 - Day ThreeThe NutraIngredients team is reporting live from the key industry event all week. We will be sharing... |
  Live from Vitafoods Europe 2013Cranberry veteran gathers forces against EU medical device productsGunter Haesaerts President, Pharmatoka |
 Guest articleEU health claims evolution: A submission rethinkNow that the dust has settled on the health claims submission process we should all be very... |
 Researchers question the 'optimal' vitamin D dose for infantsDosage recommendations for vitamin D supplementation in infancy do not help to raise levels to those considered... |
Most Popular News
Key Industry Events
Live Supplier Webinars
On demand Supplier Webinars
Probiotics: The Path to Better Digestive Health through Quality Clinical Trials
DuPont Nutrition & Health
DuPont Nutrition & Health
Alkaloids & Antioxidants
Coffee contains basically two main active compound groups: Alkaloids (Caffeine) and polyphenols (Chlorogenic acids family). There is substantial evidence to affirm that the alkaloid modulates brain function (like most of alkaloids do), but it is also true that the polyphenols in coffee regulates blood glucose and might reduce the incidence of diabetes.
What I found remarkable is that the European Food Safety Agency will approve first Health Claims for the Alkaloid instead of the Polyphenols in coffee.
Posted by Alvin Ibarra, PhD
19 November 2012 | 18h27